Cargando…

Factors Predictive of Primary Resistance to Immune Checkpoint Inhibitors in Patients with Advanced Non-Small Cell Lung Cancer

SIMPLE SUMMARY: According to the Society for Immunotherapy of Cancer, primary resistance to immune checkpoint inhibitor (ICI) treatment is defined as progression of disease within 6 months of ICI treatment with patients receiving at least 6 weeks of ICI monotherapy. We evaluated factors predictive o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Huang, Yiqing, Zhao, Joseph J., Soon, Yu Yang, Kee, Adrian, Tay, Sen Hee, Aminkeng, Folefac, Ang, Yvonne, Wong, Alvin S. C., Bharwani, Lavina D., Goh, Boon Cher, Soo, Ross A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10216169/ https://www.ncbi.nlm.nih.gov/pubmed/37345072 http://dx.doi.org/10.3390/cancers15102733

Ejemplares similares

Cytokine Release Syndrome in Cancer Patients Receiving Immune Checkpoint Inhibitors: A Case Series of 25 Patients and Review of the Literature
por: Tay, Sen Hee, et al.
Publicado: (2022)

Real‐world experience of consolidation durvalumab after concurrent chemoradiotherapy in stage III non‐small cell lung cancer
por: Huang, Yiqing, et al.
Publicado: (2022)

Clinical Presentation of Immune-Related Endocrine Adverse Events during Immune Checkpoint Inhibitor Treatment
por: Chieng, Jenny Hui Ling, et al.
Publicado: (2022)

Low‐dose pembrolizumab in the treatment of advanced non‐small cell lung cancer
por: Low, Jia Li, et al.
Publicado: (2021)

Unleashing the efficacy of immune checkpoint inhibitors for advanced hepatocellular carcinoma: factors, strategies, and ongoing trials
por: Yu, Jiahui, et al.
Publicado: (2023)

Neutrophil-to-Lymphocyte Ratio Predicts Development of Immune-Related Adverse Events and Outcomes from Immune Checkpoint Blockade: A Case-Control Study
por: Lee, Pei Yi, et al.
Publicado: (2021)

Third generation EGFR TKIs: current data and future directions
por: Tan, Chee-Seng, et al.
Publicado: (2018)

Interactions between epidermal growth factor receptor tyrosine kinase inhibitors and proton-pump inhibitors/histamine type-2 receptor antagonists in non-small cell lung cancer: a systematic review and meta-analysis
por: Sim, Wilson, et al.
Publicado: (2021)

Paraneoplastic Necrotizing Myelopathy in a Patient With Newly Diagnosed Diffuse Large B Cell Lymphoma
por: Lee, Chau Hung, et al.
Publicado: (2011)

Multinational Analysis of Estimated Health Care Costs Related to Extended-Interval Fixed Dosing of Checkpoint Inhibitors
por: Goldstein, Daniel A., et al.
Publicado: (2023)

Different treatment efficacies and side effects of cytotoxic chemotherapy
por: Li, Low-Jia, et al.
Publicado: (2020)

ABT-869, a promising multi-targeted tyrosine kinase inhibitor: from bench to bedside
por: Zhou, Jianbiao, et al.
Publicado: (2009)

Real-world assessment of attenuated dosing anti-PD1 therapy as an alternative dosing strategy in a high-income country (as defined by World Bank)
por: Low, Jia Li, et al.
Publicado: (2022)

A Cell-Based Small Molecule Screening Method for Identifying Inhibitors of Epithelial-Mesenchymal Transition in Carcinoma
por: Chua, Kian-Ngiap, et al.
Publicado: (2012)

Resistance to immune checkpoint inhibitors in non-small cell lung cancer: biomarkers and therapeutic strategies
por: Walsh, Robert J., et al.
Publicado: (2020)

Combined use of irinotecan with histone deacetylase inhibitor belinostat could cause severe toxicity by inhibiting SN-38 glucuronidation via UGT1A1
por: Wang, Lingzhi, et al.
Publicado: (2017)

UGT1A6 Polymorphisms Modulated Lung Cancer Risk in a Chinese Population
por: Kua, Ley-Fang, et al.
Publicado: (2012)

Response to Immune Checkpoint Inhibitor Treatment in Advanced Cervical Cancer and Biomarker Study
por: Shieh, Kevin R., et al.
Publicado: (2021)

A zebrafish embryo screen utilizing gastrulation identifies the HTR2C inhibitor pizotifen as a suppressor of EMT-mediated metastasis
por: Nakayama, Joji, et al.
Publicado: (2021)

Real-world outcomes from use of CDK4/6 inhibitors in the management of advanced/metastatic breast cancer in Asia
por: Low, Jia Li, et al.
Publicado: (2022)

Immune checkpoint inhibitors in renal cell carcinoma
por: Ross, Kirsty, et al.
Publicado: (2017)

Increased Reporting of Immune Checkpoint Inhibitor–Associated Diabetes
por: Wright, Jordan J., et al.
Publicado: (2018)

Association and clinical utility of NAT2 in the prediction of isoniazid-induced liver injury in Singaporean patients
por: Chan, Sze Ling, et al.
Publicado: (2017)

Combinatorial treatment using targeted MEK and SRC inhibitors synergistically abrogates tumor cell growth and induces mesenchymal-epithelial transition in non-small-cell lung carcinoma
por: Chua, Kian Ngiap, et al.
Publicado: (2015)

Dynamics of multiple resistance mechanisms in plasma DNA during EGFR‐targeted therapies in non‐small cell lung cancer
por: Tsui, Dana Wai Yi, et al.
Publicado: (2018)

A Phase II Study of Osimertinib in Patients with Advanced-Stage Non-Small Cell Lung Cancer following Prior Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR TKI) Therapy with EGFR and T790M Mutations Detected in Plasma Circulating Tumour DNA (PLASMA Study)
por: Ang, Yvonne L. E., et al.
Publicado: (2023)

The predictive value of tumor mutation burden for immune checkpoint inhibitors therapy in non-small cell lung cancer is affected by patients’ age
por: Wu, Yongfeng, et al.
Publicado: (2020)

Whole Exome Sequencing of Multi-Regional Biopsies from Metastatic Lesions to Evaluate Actionable Truncal Mutations Using a Single-Pass Percutaneous Technique
por: Heong, Valerie, et al.
Publicado: (2020)

Prevalence of established and emerging biomarkers of immune checkpoint inhibitor response in advanced hepatocellular carcinoma
por: Ang, Celina, et al.
Publicado: (2019)

The neurotoxic effects of immune checkpoint inhibitor therapy for melanoma
por: Spain, Lavinia, et al.
Publicado: (2019)

A randomized phase II trial evaluating the addition of low dose, short course sunitinib to docetaxel in advanced solid tumours
por: Ang, Yvonne L. E., et al.
Publicado: (2020)

Profile of nivolumab in the treatment of metastatic squamous non-small-cell lung cancer
por: Ang, Yvonne LE, et al.
Publicado: (2016)

Immune checkpoint inhibitors
por: Hui, Enfu
Publicado: (2019)

Immune checkpoint inhibitors
por: Kroemer, Guido, et al.
Publicado: (2021)

Checkpoint Inhibitors and Hepatotoxicity
por: Malnick, Stephen D. H., et al.
Publicado: (2021)

Checkpoint Inhibitors and the Gut
por: Tran, Tuan, et al.
Publicado: (2022)

Checkpoint inhibitor–associated cutaneous small vessel vasculitis
por: Castillo, Brianna, et al.
Publicado: (2018)

Dose modifications in Asian cancer patients with hepatic dysfunction receiving weekly docetaxel: A prospective pharmacokinetic and safety study
por: Syn, Nicholas Li‐Xun, et al.
Publicado: (2016)

Simvastatin-induced breast cancer cell death and deactivation of PI3K/Akt and MAPK/ERK signalling are reversed by metabolic products of the mevalonate pathway
por: Wang, Tingting, et al.
Publicado: (2015)

Can EGFR-Tyrosine Kinase Inhibitors (TKI) Alone Without Talc Pleurodesis Prevent Recurrence of Malignant Pleural Effusion (MPE) in Lung Adenocarcinoma
por: Verma, Akash, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_e1rvq34vqfpnprfus9tdc0t6ot